Last $5.24 USD
Change Today +0.04 / 0.77%
Volume 231.0K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Open
$5.20
Previous Close
$5.20
Day High
$5.39
Day Low
$5.15
52 Week High
09/20/13 - $9.41
52 Week Low
05/9/14 - $4.56
Market Cap
185.2M
Average Volume 10 Days
161.0K
EPS TTM
$-1.81
Shares Outstanding
35.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc. develops cell based therapeutics. The company is involved in the manufacture of cell therapy-based products; and provides product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. It also offers contract development and manufacturing services to clients advancing in the regenerative medicine industry; and collects, processes, and stores umbilical cord blood units and adult stem cells. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. In addition, it develops T regulatory cell based therapeutics to treat diseases caused by imbalances in the immune system; and researches and develops therapeutics based on very small embryonic-like technology. The company has a collaboration agreement with Becton-Dickinson. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer
Total Annual Compensation: $190.6K
Chief Scientific Officer, President of Progen...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

NeoStem, Inc. Enters into License Agreement with the Rockefeller University to Expand its Cancer Immunotherapy Intellectual Property Portfolio

NeoStem, Inc. announced that it has entered into an exclusive license agreement with The Rockefeller University for patented technologies that further expand the company's intellectual property portfolio associated with its Targeted Cancer Immunotherapy Program. The discovery of dendritic cells in 1973, resulting in a 2011 Nobel Prize in Physiology or Medicine, bridged the two principal aspects of immunity (innate and adaptive) first defined by Nobel Prize recipients in Physiology or Medicine in 1908. It was subsequently proved that dendritic cells, part of the innate immune system, orchestrate the immune response to specific antigens by absorbing antigens and, when activated, present the specific antigens to B and T cells that result in antigen specific adaptive immunity. The Rockefeller University patents licensed by NeoStem are titled: "Methods for use of Apoptotic Cells to Deliver Antigen to Dendritic Cells for Induction or Tolerization of T Cells," (inventors: Matthew Albert, Nina Bhardwaj, Ralph M. Steinman, Kayo Inaba and Robert Darnell). Dendritic cells can be removed from the body in their inactive form, loaded with antigens and then re-infused and activated leading to an antigen specific immune response, including immune responses directed against cancer antigens. This additional intellectual property from The Rockefeller University expands the breadth of the company's already comprehensive Targeted Cancer Immunotherapy Program patent portfolio, which portfolio includes inventions relating to critical aspects of a dendritic cell-based therapy, such as novel antigen-presenting cancer vaccines, stem cell growth media, and methods to produce the high purity cancer initiating (stem) cells that provide the critical antigen array with which the vaccine's dendritic cells are pulsed.

Neostem, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 11:25 AM

Neostem, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 11:25 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Robin L. Smith, Executive Chairman and Chief Executive Officer.

Neostem, Inc. Presents at Swedish-American Life Science Summit 2014, Aug-22-2014 10:30 AM

Neostem, Inc. Presents at Swedish-American Life Science Summit 2014, Aug-22-2014 10:30 AM. Venue: EY Headquarters, Stockholm, Sweden. Speakers: Hans S. Keirstead, President of NeoStem Oncology.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $5.24 USD +0.04

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $2.74 USD +0.04
Biorestorative Therapies Inc $0.37 USD -0.0005
BioTime Inc $3.79 USD +0.24
IntelliCell BioSciences Inc $0.0014 USD 0.0001
Organovo Holdings Inc $6.57 USD -0.42
View Industry Companies
 

Industry Analysis

NBS

Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit www.neostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.